Immunotherapeutic interventions are showing effectiveness across a wide range of cancer
types, but only a subset of patients shows clinical response to therapy. Responsiveness to …

For tumor antigen-specific T cells to effectively control the growth of cancer cells in vivo, they
must gain access to, and function within, the tumor microenvironment. While tumor antigen …

A pre-existing T cell-inflamed tumor microenvironment has prognostic utility and also can be
predictive for response to contemporary cancer immunotherapies. The generation of a …

Melanoma treatment is being revolutionized by the development of effective
immunotherapeutic approaches,. These strategies include blockade of immune-inhibitory …

Tumor escape from immune-mediated destruction has been associated with
immunosuppressive mechanisms that inhibit T cell activation. Although evidence for an …

Spontaneous T cell responses against tumors occur frequently and have prognostic value in
patients. The mechanism of innate immune sensing of immunogenic tumors leading to …

T cell–mediated immunotherapies are promising cancer treatments. However, most patients
still fail to respond to these therapies. The molecular determinants of immune resistance are …

Effector T cells have the capability of recognizing and killing cancer cells. However, whether
tumors can become immune resistant through exclusion of effector T cells from the tumor …

Background Blockade of immune inhibitory pathways is emerging as an important
therapeutic modality for the treatment of cancer. Single agent treatments have partial anti …

Purpose: The T-cell-inflamed phenotype correlates with efficacy of immune-checkpoint
blockade, whereas non-T-cell-inflamed tumors infrequently benefit. Tumor-intrinsic WNT/β …